Amarin Corp Plc (AMRN)

[MedResCollab]

Suspicious, one-month early increased revenue guidance? Doubling of sales reps? “Assuming” sNDA approval? A positive sign on the balance sheet? Was this really an early gift to AMRN bulls, or does management have other reasons for dropping this premature “optics” package?

We think it was a prudent, shrewd move. In our view, Amarin insiders have carefully weighed the risks and what the pending communications with FDA may mean for their ability to go to capital markets and raise significant funds. Right now they have nothing but positive to say. Within two weeks there could be an AdComm announcement, and/or FDA may request additional data, which would ultimately extend the PDUFA date. And there is also the imminent threat that FDA will issue a clinical hold on EVAPORATE.

Thus, the premature rush to get good news out, and we think probably raise cash soon.

Here is yet another example where the market, at least in the short term, is rather oblivious.

Regards,
-MRC